Hot or Not, Stock Market Edition: 04/03/2025

Cloud-based software sizzles; a pharma marketing company fizzles. Here’s what’s hot and what’s not right now: 

• HOT: Progress Software Corporation (NASDAQ: PRGS) gets a boost on raised guidance;  monday.com (NASDAQ: MNDY) gets bona fides from top-rated analysts. 

• NOT: Gorilla Technology Group (NASDAQ: GRRR) is in a “weird” place; OptimizeRx (NASDAQ: OPRX) may be losing recent momentum

P.S. For more stocks making moves, check out our new Zen Ratings Upgrades & Downgrades screener.

🔥 HOT: Shares of AI software company Progress Software Corporation (NASDAQ: PRGS) gained 12.1% on Tuesday after it raised its full-year EPS outlook range from $5.00 to $5.12 per share to $5.25 to $5.37 per share. The company’s Chief Financial Officer, Anthony Folger, said that demand for the company’s products was higher than expected for the first quarter, which caused Progress to reevaluate its guidance. PRGS has lost 12.2% YTD but is up 8.4% year-over-year and has beaten its earnings projections for the last four quarters. We give the stock a B Zen Rating and a Buy recommendation due to its attractive current value and continued potential for growth.

🥶 NOT: Gorilla Technology Group (NASDAQ: GRRR) is a stock in a weird place. On one hand, it’s gained 26.0% YTD and is up more than 200% in the last year. On the other hand, it lost 15.3% on Tuesday after underperforming in the fourth quarter of last year. GRR has traded mostly sideways since the middle of February, and its ability to grow in the current macroeconomic climate is uncertain. Still, our research gives it a solid B rating for Momentum, and its recent performance is hard to ignore. Without a clear impetus for buying or selling GRRR right now, we give the stock a C Zen Rating and a Hold recommendation.

🔥 HOT: Cloud-based project management software company monday.com (NASDAQ: MNDY) gained 7.9% on Tuesday after analysts from Jefferies and Citi maintained the stock as a top pick for 2025. MNDY is up 10.3% YTD and 17.3% year-over-year but is facing some fierce competition from similar companies like Asana, Notion, and Trello. We’re bullish on MNDY due to its recent increased focus on enterprise customers, which have better margins and lifetime values than individuals and small businesses. Overall, we give MNDY a B Zen Rating and a Buy recommendation. Our analysis gives MNDY an A Growth rating and B ratings in Sentiment and Financials. The only lagging metric is the D it gets in Safety due to recent volatility spikes. 

🥶 NOT: Pharmaceutical marketing company OptimizeRx (NASDAQ: OPRX) lost 5.7% on Tuesday as the recent momentum from its surprisingly upbeat earnings report started to fizzle. We’re always wary of pharma stocks and pharma-adjacent stocks because of their tendency to have increased volatility, but it’s hard to deny OPRX’s potential for growth. The company just announced a potential $75 million offering to raise capital ahead of what many assume to be big plans for 2025 and beyond. Our analysis gives OPRX a B rating for Growth, but otherwise, we see it as a relatively risky play. In the end, we give OPRX a C Zen Rating and a Hold recommendation.

What to Do Next?

• 8 Stock Lists You Need Now >
• See All “A” Rated Stocks with +32.52% Average Annual Return > 
• 4 Step Process to Find More 100%+ Stock Winners >

Want to get in touch? Email us at news@wallstreetzen.com.